Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03525288 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PSMA-PET Guided Radiotherapy

Study acronym: PSMA-PETgRT
StatusActive, Not Recruiting
PhasePhase 2/3
Started2018-05-15
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 13, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2025-03-12
Study Status v7
Primary completion date2024-05-30→2026-05-30
Completion date2026-04-30→2027-05-30
2023-09-05
2 amendments v5-v6
2 re-verifications since 2022-08-05, no change to tracked fields
2021-06-07
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v4
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2021-04-30→2024-05-30
Study sitesdetails revised at 3 of 3 sites
2020-05-01
Study Status, Contacts/Locations v3
Study sites1→3
2019-09-20
Study Status v2
Re-verified, no change to tracked fields
2018-05-29
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Study sites0→1
2018-05-14
Original filing
PSMA PET/CT has demonstrated higher sensitivity in detecting metastases than current imaging standard of care (CT and bone scan). \[18F\]DCFPyL is a promising high-sensitivity second generation PSMA-targeted urea-based PET probe. The hypothesis is that definitive radiotherapy (RT) informed by PSMA-PET findings will lead to improved cancer control outcomes compared to RT guided by conventional staging only. This study utilizes cmRCT design in companion to PERA (Partnership initiative for the Evaluation of technological innovation in Radiotherapy).
Trial Details
NCT Number NCT03525288
Lead Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators: Progenics Pharmaceuticals, Inc.
Conditions Prostate Cancer
Enrollment 130 participants
Start Date 2018-05-15
Primary Completion 2026-05-30 (estimated)
Study Completion 2027-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-13